Drugs / Sudapyridine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06701136 | May → Oct 2025 overdue | rifampicin-resistant tuberculosis | Shanghai Jiatan Pharmatech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06117514 | Feb 2019 → Jul 2020 | — | Shanghai Jiatan Pharmatech Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05824871 | Sep 2022 → Dec 2025 overdue | multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Shanghai Jiatan Pharmatech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sudapyridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06701136 ↗ |
| Known as | WX-081 | “In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast.” NCT06701136 ↗1“Sudapyridine (WX-081)” NCT06117514 ↗ |
| Route | Oral | “A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients” NCT05824871 ↗ |